Inclusion Criteria:

- Patients with relapsed or progressive poor prognosis tumors for which no curative
therapy exists.

- Histologic confirmation of disease at diagnosis or relapse.

- Brain stem glioma patients who have progressed after radiation therapy do not require
histologic confirmation. Duration of symptoms at the time of diagnosis must be less
than 3 months and should consist of cranial nerve deficits and/or ataxia and/or long
tract signs.

- Prior radiation therapy and/or chemotherapy are permitted.

- Karnofsky Performance Status >50. For infants, the Lansky play scale >50% can be
substituted.

- Life expectancy > 2 months.

- No active uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as ≥
grade 3 based on the common toxicity criteria.

- No known allergies to sulfonamides

- Adequate renal function: Serum Creatinine < 1.5 mg/dl or creatinine clearance or GFR
> 70 ml/min.

- Adequate hepatic function: Total Bilirubin < 1.5 mg/dl; SGOT, SGPT, Alk Phos < 3x
normal.(SGOT can be < 4x normal for patients on Zantac).

- Adequate bone marrow reserve: Hgb > 9.0 g/dl, Platelets > 75,000/mm3 (transfusion
independent),WBC > 2000/mm3 and ANC > 1000/mm3.

- Patients receiving steroids and/or anti-seizure medications are eligible for this
study.

Exclusion Criteria:

- Patients must not be pregnant or nursing, and all patients of child bearing age (both
male and female) must be willing to practice birth control during and for 2 months
after treatment with thalidomide. If the patient is unable to use oral contraceptives
for medical reasons, 2 different barrier methods may be used if approved by the
treating physician.

- No concurrent use of other investigational agents.

- Patients that have received more than 2 months of oral therapy with any of the agents
used in this study will be ineligible. Standard administration of IV etoposide and
cyclophosphamide, usually administered in 3-week cycles is permitted.